Longevity & AgingPress Release

FDA Approves Giredestrant, a New Oral Option for Resistant Advanced Breast Cancer

The FDA approved Roche's oral drug Wilserdly (giredestrant) for ESR1-mutated, HR-positive advanced breast cancer, offering a new option when tumors resist standard therapy.

Tuesday, November 17, 2026 0 views
Published in STAT News
Article visualization: FDA Approves Giredestrant, a New Oral Option for Resistant Advanced Breast Cancer

Summary

The FDA has approved Wilserdly (giredestrant), an oral breast cancer drug from Roche. It is cleared for adults with advanced breast cancer that is hormone receptor-positive and HER2-negative and has developed a mutation in the ESR1 gene. That mutation signals the tumor is becoming resistant to standard hormone-blocking treatments. Giredestrant belongs to a class called selective estrogen receptor degraders, or SERDs, which break down the estrogen receptor that fuels these tumors. In the evERA trial, the drug lengthened the time before tumors progressed. Roche has said it could become its top-selling product ever, and the approval strengthens its position in breast cancer, where it has fallen behind rivals in recent years. For patients with resistant disease, it adds a convenient pill-based option. The available excerpt is brief, so details on how large the benefit was, side effects, and overall survival are not yet clear.

Detailed Summary

Breast cancer is the most common cancer in women, and hormone receptor-positive, HER2-negative disease is its largest subtype. These tumors depend on estrogen signaling, so most patients receive endocrine therapy. Over time, many tumors acquire resistance, and a common route is a mutation in the ESR1 gene, which encodes the estrogen receptor. New options for this setting matter because treatment choices narrow once resistance emerges.

The FDA has now approved Roche's Wilserdly, also known as giredestrant, for patients with HR-positive, HER2-negative advanced breast cancer carrying an ESR1 mutation. Giredestrant is an oral selective estrogen receptor degrader, or SERD. Rather than just blocking the receptor, SERDs mark it for destruction, which can help overcome mutation-driven resistance.

The approval rests on the evERA trial, which showed that the drug extended the time before patients' tumors progressed. The excerpt available does not give the size of that benefit, the comparison arm details, safety findings, or whether survival improved. Those details will matter for judging how meaningful the advance is.

The decision is also commercially significant. Roche has said the drug could become its best-selling product ever, and it gives the company a renewed foothold in breast cancer, a field in which its subsidiary Genentech built its reputation with Herceptin but where it has lagged competitors in recent years.

Practically, the approval gives oncologists another oral option for a defined, biomarker-selected group, reinforcing the value of testing tumors for ESR1 mutations when disease progresses on endocrine therapy. Caveats: this summary is based on a truncated news report behind a paywall. Readers should consult the FDA label, the evERA publication, and their oncology team for efficacy, side effects, and how the drug compares with existing SERDs.

Key Findings

  • FDA approved Roche's oral SERD Wilserdly (giredestrant) for HR-positive, HER2-negative advanced breast cancer with an ESR1 mutation.
  • ESR1 mutations signal that a tumor is developing resistance to standard endocrine treatments.
  • The evERA trial showed giredestrant extended time before tumor progression.
  • Roche has said the drug could become its top-selling product ever.
  • Approval is limited to a biomarker-selected group, underscoring the role of ESR1 mutation testing.

Methodology

This is a news report on a regulatory decision from STAT News, a credible health outlet. The visible text is a truncated paywalled excerpt. Evidence cited is the evERA trial, but no data are shown.

Study Limitations

Effect size, safety, survival data, and comparisons with other SERDs are not in the excerpt. Verify details in the FDA label and the published evERA results.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: